and low cost of conventional iHD. Now-a-days it is also called prolonged intermittent renal replacement therapy (PIRRT). 1 Many critically ill patients in ICU are either hypotensive or have some other cardiovascular problems which make them unsuitable for iHD. Though CRRT offers greater hemodynamic stability than iHD for ICU patients, the costly CRRT machine is not widely available in resource poor settings. Moreover, many patients find it very difficult to bear the cost of CRRT. The aim of the present study was to evaluate the hemodynamic tolerability of SLED in the critically ill patients of ICU suffering from AKI.
Methods

Bangladesh Institute of Research and Rehabilitation in
Diabetes, Endocrine and Metabolic Disorder (BIRDEM) General Hospital is a tertiary care academic hospital in Dhaka, the capital of Bangladesh. It had an adult mixed (medical and surgical) ICU comprising of 10 beds. This Quasi-experimental study was conducted in this ICU after getting approval from the Ethical Review Committee of Bangladesh Diabetic Somiti. AKI patients who were admitted in this ICU or who developed AKI after admission from 1 st June 2012 to 31 st May 2013, were enrolled if they had hemodynamic instability.
Hemodynamic instability was defined as the composite of the following events: hypotension which needed treatment with inotropes/vasopressors and/or compromised cardiac function (left ventricular ejection fraction <35%). Hemodynamically unstable patients who were not fit for iHD were chosen for SLED and informed written consents were taken from individual patient or from their legal guardian for participation in the study. Exclusion criteria were patients suffering from end stage renal disease (ESRD) before ICU admission and consent denial.
SLED sessions were administered with the Dialog + B Braun hemodialysis machine without any additional hardware or software. F8 low flux polysulfone hemodialyzer was used with standard lines. As the minimum dialysate flow rate in Dialog + B Braun hemodialysis machine is 300 ml/min, this was set as the dialysate flow for every SLED session. The blood flow rates varied from 100 to 150 ml/min according to patients' blood pressure (BP) and/or dose of inotropes/ vasopressors. The desired ultrafiltration volumes were prescribed by the intensivist.
Each SLED session was planned to deliver for 6 hours and was administered by ICU nurses. Hemodynamic monitoring and decisions regarding vasopressor dosing and anticoagulants were done by the ICU physicians.
A preformed data sheet was used for collecting data from each patient. Demographic informations like age, gender etc, diagnoses at the time of ICU admission and reason for giving SLED were documented on the day of SLED initiation. Blood tests like complete blood count, coagulation screening, blood urea, serum creatinine, serum electrolytes and arterial blood gas analyses were recorded on admission to ICU, on day of RRT initiation and after each RRT session. Systolic and diastolic BP, mean arterial pressure (MAP), pulse, temperature, respiratory rate and vasopressor/inotrope requirements were recorded at the beginning of SLED, during SLED sessions and at the end of the therapy. Vasopressor/inotropes included norepinephrine, dopamine, vasopressin, epinephrine and/or dobutamine. Data were collected for 1 st seven days after initiation of SLED and patients were followed up for 28 days for outcome. Outcomes were documented as resolution of AKI or continuation of RRT or death within 28-days of initiation of SLED.
Hemodynamic instability was decided when any patient developed any form of arrhythmia during SLED sessions or intra-therapy drop in MAP from the pre-SLED value or need to escalate the dose of vasopressor/inotrope or addition of a vasopressor/inotrope. If hypotension or arrhythmia persisted for more than half an hour after giving adequate treatment or if MAP dropped more than 20% from pre-SLED MAP, RRT was discontinued and that SLED session was marked as 'treatment failure'. Statistical analyses were done by SPSS 17 for Windows. Comparison was performed using t-test, and anova. P less than 0.05 was considered as significant.
Results
During the study period, 43(including 29 male) hemodynamically unstable patients with AKI received SLED in the study ICU. Mean age of the patients was 60.12±14.57 years. The commonest diagnosis during ICU admission was pneumonia (46.5%) followed by acute myocardial infarction (AMI, 41.9%). Indications of choosing SLED were cardiogenic shock and ischemic heart disease (IHD) with compromised cardiac function (n=20, 46.5%) and septic shock (n=18, 41.9%). One patient had chronic liver disease with low BP (Systolic BP <90 mmHg) and another patient had severe hyponatremia (serum sodium <120 mmol/L). So, SLED was given to treat AKI in these two patients also. Three patients were suffering from both cardiogenic and septic shock.
Thirty out of 43 patients required inotrope/vasopressor before initiation of SLED to maintain their BP. Twenty five patients were put on mechanical ventilator (MV) support after ICU admission. Other baseline variables are shown in table I. The following table (Table III) show the MAP of the patients' which were recorded before initiation of each session of SLED, during SLED and after completion of the treatment. There were no significant changes of MAP during the procedure.
There were no significant changes in pulse, R/R and temperature during and after SLED sessions.
One hundred and seventeen sessions of SLED could be performed without any complication. Only thirty six (23.52%) sessions were associated with complications shown in figure 1. The commonest complication was hypotension (n=31 sessions) which required increase in dosage of inotrope or addition of inotrope. But no 5 Though solute and fluid removal are slower than conventional iHD, but faster than CRRT; several prospective controlled studies have shown that SLED clears small solutes with an efficacy comparable to that of iHD and CRRT. At the same time it is less expensive than CRRT. 6, 7 So, SLED combines the therapeutic advantages of CRRT with the logistic and cost advantages of iHD. Our study aimed to investigate the hemodynamic stability in critically ill patients with AKI treated with SLED. This is the first study of SLED done on ICU patients of Bangladesh.
All of our patients showed excellent hemodynamic stability with SLED treatment. Changes in MAP before SLED, during treatment and after dialysis were not significant (p>0.05 in all sessions). This maintained hemodynamic stability might be the result of the extended duration of the SLED treatment (5.75 ± 1.2 hours) along with low dialysate flow (300ml/min). None of our treatment had to be discontinued because of hypotension as the hypotensive sessions were managed with increasing the dose of inotropes or adding another inotrope/vasopressor. Our findings contribute to an expanding literature supporting the use of SLED in critically ill patients in circumstances where CRRT would typically be considered. 1, 5 dialysis had to be discontinued for any of the complications. No complication due to heparin occurred in any of the dialysis sessions which were done with heparin (n=77).
Figure-1: Pie chart showing percentage of SLED sessions associated with and without complications
Nearly seventy percent patients required inotrope prior to SLED and inotropes/vasopressors were employed at 85 sessions of SLED out of 153. Though 31 sessions required increasing the dose of vasopressor/inotrope during dialysis, none of the treatment session had to be discontinued because of hypotension (Table V) . Inotrope dose could be decreased only in 6 sessions out of 153 SLED. There is a concern that hypotension during RRT may be detrimental to renal recovery. 8 In a study done by Marshall et al, SLED was hemodynamically tolerated in most patients (MAP pre-SLED 69.1 mmHg and post-SLED 68.9 mmHg, p=0.26) though hypotension did occur during treatment and necessitated discontinuation in 7.6% sessions. 9 But there was significant intradialytic decrease in MAP in the study by Kumar N. (MAP pre-SLED 103.3 mmHg and post-SLED 78.6 mmHg, p=<0.001). 10 In our study, 31 (20.26%) SLED sessions were associated with one or more episodes of hypotension defined as MAP less than 65 mmHg. So, these sessions required an increase in vasopressor dose or addition of another inotrope. But, none of the dialysis had to be discontinued because of hypotension and there was no significant differences in pre-, during and post-SLED MAP (p>0.05). The hypotensive episodes may be explained by the rapid removal of water and solutes during dialysis. The fluid and solute removal in iHD occurs over a short period of time (4 hours every alternate day), but over a longer period in CRRT (at least 24 hours, commonly 3-5 days). So, the hemodynamically unstable patients cannot tolerate iHD. In case of SLED, fluid and solutes are removed over 6-12 hours time, which is longer than iHD but shorter than CRRT. The decline in blood pressure in our ICU patients is explained by this relatively rapid removal of water and solutes. It is pertinent to note that in some previous studies, the SLED was found to be hemodynamically well tolerated even by the critically ill patients on inotropic support and its effect on hemodynamic variables was found to be comparable with continuous veno-venous hemodiafiltration (CVVH). 9,11 Kielstein et al. had to increase the dose of inotropes in 25% study subjects, the dose remained unchanged in 25% and could be reduced in 50%. 12 .
Vital signs of the patients were monitored meticulously through the course of dialysis. There were no significant differences in pre-and post-SLED pulse rate and respiratory rate which strongly support in favor of hemodynamic tolerability of SLED. Fliser reported significant reduction in core temperature (37.4 ± 0.3p C to 36.7 ± 0.2p C, p<0.05) while performing SLED in septic patients. 13 This decrease in core temperature could actually be advantageous as it increases peripheral resistance and improves cardiovascular stability. But we did not find any significant change in temperature among our patients. It may be explained by the fact that we included not only septic patients but also other patients. Twenty one out of 43 patients had severe sepsis and the rest did not have any infection. The mean temperature of the study subjects before initiation of SLED was 99.51 ± 1.335 °F and ranged from 98° to 103°F. This indicates that all patients with sepsis did not have hyperthermia. Antimicrobials were started as soon as possible in patients with septic shock which also explains the reason behind the mean temperature of 99.5°F.
A potentially complicating factor is the more intensified anticoagulation for CRRT due to longer treatment time required to prevent clotting of the extracorporeal circuit. SLED can be performed without the need for systemic anticoagulation. Earlier studies by Kumar, Kielstein and Berbece demonstrated a significantly lower need for anticoagulation in SLED-treated patients. 11, 12, 14 In our study, we conducted 76 (49.6%) sessions without heparin as the patients had coagulopathy. Though dialyzer and circuit clotting occurred in 5 of these sessions, dialysis treatments could be re-started after clearing the circuits and filter. So, it is an additive advantage of SLED for the critically ill patients with severe bleeding diathesis.
An important aspect, especially in the developing countries, might be the cost. There is a markedly lesser cost of the circuit tubing, membranes and the machines used in SLED than those used in CRRT. In fact, all centers across the world offering SLED use various standard iHD machines without adding or altering any software or hardware. 15 In our ICU, we also used the hemodialysis machine which resulted in substantial cost reduction.
Overall, SLED was tolerated well by the critically ill patients and widely accepted by our ICU staff. SLED has been adopted worldwide on a significant scale. 1 6 Recent data demonstrate that neither the technique of RRT 4,17 nor the dose of RRT 18, 19 had an impact on patient survival. In the light of markedly higher costs of CRRT, it was therefore suggested that, in the absence of a survival benefit of CRRT, slow continuous therapy like SLED should be the preferred treatment modality for AKI in ICU. 1, 20, 21 In Bangladesh, hemodialysis machines are available in many places. As SLED can be given with iHD machine, this new RRT can be safely conducted in ICU for management of AKI of the critically ill patients.
Limitations
Sample size in this study was small; so the findings derived from the study cannot be generalized to reference population and the data should be interpreted with utmost caution. As all the ICU patients are critically ill requiring RRT, we could neither have any control group who could be treated without RRT, nor any control group who could be treated with CRRT due to financial problem. There was only one HD machine in ICU, BIRDEM. So, it was not technically possible to treat the study subjects with daily SLED. It was also difficult to treat the study subjects with SLED sessions consisting of 8 hours or more due to same reason.
Conclusion
SLED is a slower dialytic modality which is ran for prolonged periods using conventional hemodialysis machines with modification of blood and dialysate flows. This study concludes that SLED maintains hemodynamic stability in the critically ill patients of ICU. In a country like Bangladesh with limited health care resources, SLED is a practical and attractive RRT for the AKI patients who are hemodynamically unstable. As hemodialysis machines are now available in many parts of our country, SLED appears to be a promising technique for the critically ill patients of ICUs suffering from renal failure.
